Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–62.

Article  CAS  PubMed  Google Scholar 

Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. Int J Cancer (2021).

Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.

Article  CAS  PubMed  Google Scholar 

Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.

Article  CAS  PubMed  Google Scholar 

Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282–96.

Article  CAS  PubMed  Google Scholar 

Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:995–1008.

Article  CAS  PubMed  Google Scholar 

Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

Article  CAS  PubMed  Google Scholar 

Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–93.

Article  PubMed  Google Scholar 

Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862–73.

Article  CAS  PubMed  Google Scholar 

Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80.

Article  PubMed  Google Scholar 

Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10:181–223.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors European organization for research and treatment of cancer national cancer institute of the United States national cancer institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

Article  CAS  PubMed  Google Scholar 

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.

Article  CAS  PubMed  Google Scholar 

Hiraoka A, Michitaka K, Kumada T, et al. Validation and Potential of Albumin-Bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer. 2017;6:325–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550–8.

Article  PubMed  Google Scholar 

Scheiner B, Pomej K, Kirstein MM, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2022;76:353–63.

Article  CAS  PubMed  Google Scholar 

Kuzuya T, Kawabe N, Hashimoto S, et al. Early changes in alpha-fetoprotein are a useful predictor of efficacy of atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma. Oncology. 2022;100:12–21.

Article  CAS  PubMed  Google Scholar 

Zhu AX, Dayyani F, Yen CJ, et al. Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab + bevacizumab treatment of hepatocellular carcinoma. Clin Cancer Res. 2022;28:3537–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eso Y, Takeda H, Taura K, et al. Pretreatment neutrophil-to-lymphocyte ratio as a predictive marker of response to atezolizumab plus bevacizumab for hepatocellular carcinoma. Curr Oncol. 2021;28:4157–66.

Article  PubMed  PubMed Central  Google Scholar 

Hatanaka T, Kakizaki S, Hiraoka A, et al. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Hepatol Int 2022.

Myojin Y, Kodama T, Sakamori R, et al. Interleukin-6 Is a circulating prognostic biomarker for hepatocellular carcinoma patients treated with combined immunotherapy. Cancers (Basel) 2022; 14.

Liu Y, Xun Z, Ma K, et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol 2023.

Sodhi CP, Phadke SA, Batlle D, et al. Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin. Am J Physiol Renal Physiol. 2001;280:F667–74.

Article  CAS  PubMed  Google Scholar 

Noda M, Rodan GA. Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone. J Cell Biol. 1989;108:713–8.

Article  CAS  PubMed  Google Scholar 

Carbone F, Grossi F, Bonaventura A, et al. Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. Clin Exp Metastasis. 2019;36:449–56.

Article  CAS  PubMed  Google Scholar 

Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012;55:483–90.

Article  CAS  PubMed  Google Scholar 

Dai J, Peng L, Fan K, et al. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene. 2009;28:3412–22.

Article  CAS  PubMed  Google Scholar 

Wu Q, Li L, Miao C, et al. Osteopontin promotes hepatocellular carcinoma progression through inducing JAK2/STAT3/NOX1-mediated ROS production. Cell Death Dis. 2022;13:341.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu Y, Yang J, Xu D, et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut. 2019;68:1653–66.

Article  CAS  PubMed  Google Scholar 

Tada T, Kumada T, Hiraoka A, et al. Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. Sci Rep. 2021;11:14474.

Article  CAS  PubMed  PubMed Central  Google Scholar